Fortrea places sites and investigators at the forefront of clinical trial planning, leveraging their perspectives to drive changes that will improve the speed of trial execution, ease study start up and increase recruitment efficiency. These changes address long-standing challenges within clinical trials and will result in a better site, patient and sponsor trial experience.
“Sites and investigators are critical to the industry at every stage of clinical development, and they traditionally have faced hard-to-solve challenges in clinical trials alone. We welcome their insights in protocol design and actively engage them in early conversations with our operational teams and sponsors to quickly establish the most efficient, patient-focused trial plans,” said
Inaugural members of Fortrea’s
What Fortrea’s
“We firmly believe that this collaborative approach, bringing together both CRO and sites, will enable all stakeholders to align more effectively on perspectives within the clinical trial market,” said Łukasz Bęczkowski, chief operating officer at Pratia. “This, undoubtedly, empowers us to act together in a more efficient manner. Initiatives like these play a crucial role in propelling us all towards positive and expedited changes.”
“Fortrea is taking a 'listen first' approach by giving sites an equal voice towards the most effective working practices for dynamic patient communities and site stakeholders, leading to the best service to clinical trial sponsors,” said
“Fortrea is leading the industry in making partnerships more productive and efficient, from trial process to business relationships, all in the effort to accelerate new products to market,” said
“Providing the appropriate patient access solution is vital in determining the ultimate success of a clinical trial. Historically, care providers have not been involved in the early development of research planning and strategy,” said
“FutureMeds is delighted to join the
“Working across the vast clinical trial ecosystem is complex and requires highly functional partnerships centered on trust and competence,” said
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology-enabled trial solutions and post-approval services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of about 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.
Fortrea Contacts:
Fortrea Media:
Fortrea Media:
![](https://ml.globenewswire.com/media/YWY1YjEyZjgtYTY3ZS00NzZlLWI3OWUtNTYzNTliM2RmZWYzLTEyNjk2NzY=/tiny/Fortrea-Holdings-Inc.png)
2023 GlobeNewswire, Inc., source